A5000965942- CRISPR and Genetic Engineering
- CAR-T cell therapy research
- HIV Research and Treatment
- Cytomegalovirus and herpesvirus research
- T-cell and B-cell Immunology
- Amino Acid Enzymes and Metabolism
- Brain Metastases and Treatment
- Biomedical Research and Pathophysiology
- Advanced biosensing and bioanalysis techniques
- Immune Cell Function and Interaction
- Glioma Diagnosis and Treatment
- Virus-based gene therapy research
- Chemokine receptors and signaling
Tel Aviv University
2020-2022
Tel Aviv Sourasky Medical Center
2021-2022
ABSTRACT HIV viremia can be controlled by chronic antiretroviral therapy. As a potentially single-shot alternative, B cells engineered CRISPR/Cas9 to express anti-HIV broadly neutralizing antibodies (bNAbs) are capable of secreting high antibody titers. Here, we show that, upon immunization mice, adoptively transferred home germinal centers (GC) where they predominate over the endogenous response and differentiate into memory plasma while undergoing class switch recombination (CSR)....
Development of resistance to chemo- and immunotherapies often occurs following treatment melanoma brain metastasis (MBM). The microenvironment (BME), particularly astrocytes, cooperate toward MBM progression by upregulating secreted factors, among which we found that monocyte chemoattractant protein-1 (MCP-1) its receptors, CCR2 CCR4, were overexpressed in compared with primary lesions. Among other sources MCP-1 the brain, show cells altered astrocyte secretome evoked expression secretion,...
SUMMARY Multiple ongoing clinical trials use site-specific nucleases to disrupt T cell receptor (TCR) genes in order allow for allogeneic therapy 1–5 . In particular, the first U.S. trial using CRISPR-Cas9 entailed targeted disruption of TCR chains and programmed death protein 1 (PDCD1) cells refractory cancer patients 6 Here, we used same guide RNA sequences applied single-cell sequencing (scRNAseq) more than 7000 primary human cells, transfected with CRISPR-Cas9. Four days...
HK022 coliphage site-specific recombinase Integrase (Int) can catalyze integrative recombination and recombinase-mediated cassette exchange (RMCE) reactions in mammalian cell cultures. Owing to the promiscuity of 7 bp overlap sequence its att sites, active 'attB' sites flanking human deleterious mutations were previously identified that may serve as substrates for RMCE future potential gene therapy. However, wild type Int proved inefficient catalyzing such reactions. To address this low...
ABSTRACT As a potential single-shot HIV therapy, transplanted engineered B cells allow robust secretion of broadly neutralizing antibodies (bNAbs). However, ex vivo engineering autologous is expensive and requires specialized facilities, while allogeneic cell therapy necessitates MHC compatibility. Here, we develop in engineering, by injecting two adeno associated viral vectors, one coding for saCas9 another bNAb. Following immunizations, demonstrate memory retention bNAb at titers. We...
Abstract HIV viremia can be controlled by chronic antiretroviral therapy. As a potentially single-shot alternative, B cells engineered CRISPR/Cas9 to express anti-HIV broadly neutralizing antibodies (bNAbs) were shown capable of secreting high antibody titers. Here, we demonstrate that, upon immunization mice, adoptively transferred home germinal centers (GC) where they predominate over the endogenous response and differentiate into memory plasma while undergoing class switch recombination...
Abstract A potential single-shot HIV therapy may be transplanted engineered B cells allowing strong secretion of broadly neutralizing antibodies (bNAbs). However, extensive, and expensive ex-vivo manipulations performed in specialized facilities hinders clinical this approach. Furthermore, allogeneic cell necessitates MHC-II compatibility to receive mandatory T-cell help. To overcome these limitations, we engineer in-vivo. In particular, demonstrate that a single, systemic dose dual AAV, one...